Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C61565
http://purl.obolibrary.org/obo/NCIT_C61565
|
|---|---|
| Preferred Name | Bendamustine Hydrochloride |
| Definitions |
The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators. |
|---|---|
| prefLabel | Bendamustine Hydrochloride
|
| label | Bendamustine Hydrochloride
|
| PDQ_Closed_Trial_Search_ID | 350251
|
| code | C61565
|
| prefixIRI | NCIT:C61565
|
| in_subset |
See more
See less
|
| Display_Name | Bendamustine Hydrochloride
|
| Preferred_Name | Bendamustine Hydrochloride
|
| FDA_UNII_Code | 981Y8SX18M
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C16H21Cl2N3O2.ClH
|
| Maps_To | Bendamustine Hydrochloride
|
| CAS_Registry | 3543-75-7
|
| NSC Number | 138783
|
| NCI_Drug_Dictionary_ID | 350251
|
| Legacy Concept Name | Bendamustine_Hydrochloride
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A drug used to treat chronic lymphocytic leukemia (CLL). It is also used to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs.It is being studied in the treatment of other types of cancer. Bendamustine hydrochloride may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 350251
|
| Accepted_Therapeutic_Use_For | chronic lymphocytic leukemia
|
| Semantic_Type |
Pharmacologic Substance
Nucleic Acid, Nucleoside, or Nucleotide
|
| UMLS_CUI | C0772139
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |